A Rabbit Langendorff Heart Proarrhythmia Model: Predictive Value for Clinical Identification of Torsades de Pointes

The rabbit isolated Langendorff heart model (SCREENIT) was used to investigate the proarrhythmic potential of a range of marketed drugs or drugs intended for market. These data were used to validate the SCREENIT model against clinical outcomes.

[1]  A. Camm,et al.  Drug induced QT prolongation and torsades de pointes , 2003, Heart.

[2]  M. Curtis,et al.  Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia. , 1988, Cardiovascular research.

[3]  Derek Leishman,et al.  Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. , 2002, Current opinion in drug discovery & development.

[4]  L. Hondeghem.  Computer Aided Development of Antiarrhythmic Agents with Class IIIa Properties , 1994, Journal of cardiovascular electrophysiology.

[5]  F. Marchlinski,et al.  Electrocardiographic Patterns of Superior Right Ventricular Outflow Tract Tachycardias: Distinguishing Septal and Free‐Wall Sites of Origin , 2003, Journal of cardiovascular electrophysiology.

[6]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[7]  W. Weintraub,et al.  The Seattle angina questionnaire: reliability and validity in women with chronic stable angina. , 2002, Heart disease.

[8]  John Cotton,et al.  Introductory statistics. 3rd ed. , 1978 .

[9]  E. Kadyszewski,et al.  QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome , 2005, British journal of pharmacology.

[10]  D. Escande,et al.  Comparative effects of three class I antiarrhythmic drugs on plateau and pacemaker currents of sheep cardiac Purkinje fibres. , 1988, Cardiovascular research.

[11]  Peter J. Schwartz,et al.  Diagnostic Criteria for the Long QT Syndrome An Update , 1993, Circulation.

[12]  G. Breithardt,et al.  Divergent Proarrhythmic Potential of Macrolide Antibiotics Despite Similar QT Prolongation: Fast Phase 3 Repolarization Prevents Early Afterdepolarizations and Torsade de Pointes , 2002, Journal of Pharmacology and Experimental Therapeutics.

[13]  J. Papp,et al.  Effect of disopyramide on potassium currents in rabbit ventricular myocytes , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.

[14]  S. Choudhri,et al.  Retrospective Analysis of the Safety Profile of Oral Moxifloxacin in Elderly Patients Enrolled in Clinical Trials , 2005, Drug safety.

[15]  G. Duker,et al.  Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic , 2001, Circulation.

[16]  R. Passman,et al.  Torsades de pointes due to drug interaction between disopyramide and clarithromycin. , 1999, Heart disease.

[17]  A. Hoes,et al.  Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. , 2005, European heart journal.

[18]  C. Antzelevitch,et al.  Molecular mechanisms underlying the long QT syndrome. , 2002, Current opinion in cardiology.

[19]  R. L. Martin,et al.  A 3,4-diaminopyridine-insensitive, Ca(2+)-independent transient outward K+ current in cardiac ventricular myocytes. , 1994, The American journal of physiology.

[20]  Serge Richard,et al.  Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres , 2005, British journal of pharmacology.

[21]  D. Roden,et al.  Risperidone Prolongs Cardiac Repolarization by Blocking the Rapid Component of the Delayed Rectifier Potassium Current , 2003, Journal of cardiovascular pharmacology.

[22]  J. Brachmann,et al.  Electrocardiographic and Clinical Predictors of Torsades de Pointes Induced by Almokalant Infusion in Patients with Chronic Atrial Fibrillation or Flutter: A Prospective Study , 1998, Pacing and clinical electrophysiology : PACE.

[23]  N. Benowitz,et al.  Poisoning Due to Class IA Antiarrhythmic Drugs , 1990 .

[24]  R. Shah,et al.  Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. , 2005, Heart rhythm.

[25]  P. Hoffmann,et al.  Blinded Test in Isolated Female Rabbit Heart Reliably Identifies Action Potential Duration Prolongation and Proarrhythmic Drugs: Importance of Triangulation, Reverse Use Dependence, and Instability , 2003, Journal of cardiovascular pharmacology.

[26]  Timothy H. Montague,et al.  Evaluation of vardenafil and sildenafil on cardiac repolarization. , 2004, The American journal of cardiology.

[27]  N. Benowitz,et al.  Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide. , 1990, Drug safety.

[28]  Ph.D Edward Carmeliet M.D..  Use-dependent block of the delayed K+ current in rabbit ventricular myocytes , 2004, Cardiovascular Drugs and Therapy.

[29]  Todd Wisialowski,et al.  Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. , 2004, European journal of pharmacology.

[30]  P. Volders,et al.  Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. , 2006, Pharmacology & therapeutics.

[31]  E. Carmeliet.  Use-dependent block of the delayed K+ current in rabbit ventricular myocytes , 1993, Cardiovascular drugs and therapy.

[32]  F. Esmailian,et al.  Azimilide Inhibits Multiple Cardiac Potassium Currents in Human Atrial Myocytes , 2002, Journal of cardiovascular pharmacology and therapeutics.

[33]  K. Sunagawa,et al.  Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. , 2005, Journal of the American College of Cardiology.

[34]  J. Valentin,et al.  Nonclinical proarrhythmia models: predicting Torsades de Pointes. , 2005, Journal of pharmacological and toxicological methods.

[35]  M. Lehmann,et al.  Sex difference in risk of torsade de pointes with d,l-sotalol. , 1996, Circulation.

[36]  Charles Antzelevitch,et al.  Assessing predictors of drug-induced torsade de pointes. , 2003, Trends in pharmacological sciences.

[37]  T. Ohe,et al.  Induction of TU Abnormalities in Patients with Torsades de Pointes , 1992, Annals of the New York Academy of Sciences.

[38]  Hua-rong Lu,et al.  Detection of Proarrhythmia in the Female Rabbit Heart: , 2003, Journal of cardiovascular electrophysiology.

[39]  Y. Hara,et al.  Pirmenol inhibits muscarinic acetylcholine receptor-operated K+ current in the guinea pig heart. , 1997, European journal of pharmacology.

[40]  B. Small,et al.  Evidence for gender differences in electrophysiological properties of canine Purkinje fibres , 2004, British journal of pharmacology.

[41]  M. Malik.  Detection of drug-induced proarrhythmia: balancing preclinical and clinical studies. , 2005, Heart rhythm.

[42]  G. Gintant,et al.  The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis , 2001, Journal of cardiovascular pharmacology.

[43]  Marc A. Vos,et al.  Electrophysiological Safety of Sertindole in Dogs with Normal and Remodeled Hearts , 2003, Journal of Pharmacology and Experimental Therapeutics.

[44]  P. Volders,et al.  Sudden cardiac death in dogs with remodeled hearts is associated with larger beat–to–beat variability of repolarization , 2005, Basic Research in Cardiology.

[45]  C. Oliphant,et al.  Quinolones: a comprehensive review. , 2002, American family physician.

[46]  A. Camm,et al.  Mortality in Patients After a Recent Myocardial Infarction: A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification , 2004, Circulation.

[47]  W. Vieweg.  New Generation Antipsychotic Drugs and QTc Interval Prolongation. , 2003, Primary care companion to the Journal of clinical psychiatry.

[48]  T. Bridal,et al.  Voltage-dependent inhibition of the ATP-sensitive K+ current by the class Ia agent disopyramide in cat ventricular myocytes. , 1995, Journal of Pharmacology and Experimental Therapeutics.